Entrectinib for treating NTRK fusion-positive solid tumours – guidance (TA644)

Entrectinib is recommended, within the Cancer Drugs Fund as an option for NTRK fusion +ve solid tumours in adults and children 12 years and older if: the disease is locally advanced/metastatic and not for surgery, and they have not had an NTRK inhibitor.


National Institute for Health and Care Excellence